Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets

Michelle Ojemuyiwa; Karen Zeman; Alexander Spira; Bryan Oronsky; Carolyn Ray; Jane B Trepel; Min-Jung Lee; Ifeyinwa Onyiuke; Christina Brzezniak

doi:10.1002/ccr3.1880

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets

Clin Case Rep. 2018 Nov 5;6(12):2478-2481. doi: 10.1002/ccr3.1880. eCollection 2018 Dec.

Authors

Michelle Ojemuyiwa¹, Karen Zeman¹, Alexander Spira², Bryan Oronsky³, Carolyn Ray⁴, Jane B Trepel⁵, Min-Jung Lee⁵, Ifeyinwa Onyiuke⁶, Christina Brzezniak¹

Affiliations

¹ Walter Reed National Military Medical Center Bethesda Maryland.
² Virginia Cancer Specialists (VCS) Fairfax Virginia.
³ EpicentRx San Diego California.
⁴ St. Francis Hospital & Medical Center Hartford Connecticut.
⁵ Developmental Therapeutics Branch National Cancer Institute, NIH Bethesda Maryland.
⁶ VA Connecticut Health Care System West Haven Connecticut.

Abstract

Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-α inhibitor, RRx-001, in a Phase II clinical trial.

Keywords: RRx‐001; macrophage repolarization; neuroendocrine cancer; platinum doublets; priming; prostate cancer.

Publication types

Case Reports